<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03849729</url>
  </required_header>
  <id_info>
    <org_study_id>HJM0367/17-IQF</org_study_id>
    <nct_id>NCT03849729</nct_id>
  </id_info>
  <brief_title>Effectiveness and Tolerability of Phentermine in Patients Under Bariatric Surgery</brief_title>
  <official_title>Effectiveness and Tolerability of Phentermine in the Reduction of Intrahepatic Fat Infiltration, Adipose Tissue and Postoperative Complications in Patients Under Bariatric Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Juarez de Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Juarez de Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Surgical management of Morbid Obesity is increasingly frequent. A low-calorie diet is
      recommended with the main goal of reducing intrahepatic fat infiltration, fat tissue and
      making easier the surgery. Information the use pharmacological interventions during the
      preoperative period in this population are rare.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, control trial to investigate the effect and safety of Phentermine in
      patients with obesity who need a bariatric surgery (BMI &gt;35 kg/m2 with comorbidities or BMI &gt;
      40 kg/m2).

      Screening will be made to select eligible participants before intervention. Participants were
      randomly assigned to one of two groups (low-calorie diet + phentermine 15 mg or low-calorie
      diet + placebo) for therapies during 6 weeks. Anthropometric measurements (weight, body
      composition, body mass index and waist-hip index), serum metabolic profile (glucose, total
      cholesterol, HDL-c, LDL-c, triglycerides, and HOMA-IR) markers of inflammation (IL-1, IL-6
      and PCR) and hepatic ultrasound will be measured 2 times for each participant. Surgical
      complications (anastomosis filtration, intestinal obstruction or stenosis, need to perform
      open surgery and mortality) will be evaluated. Adverse events associated with phentermine
      (blood pressure, cardiac frequency, headache, gastrointestinal symptoms, euphoria, anxiety
      and insomnia) will be collected.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Experimental, analytic, comparative, prospective, longitudinal and double-blinded study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>double-blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Intrahepatic fat</measure>
    <time_frame>Change from baseline after 6 weeks treatment based on hepatic ultrasound.</time_frame>
    <description>Intrahepatic fat semi-qualitative asessment: mild(&lt;20%), moderate (20-30%), severe (&gt;30%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fat tissue</measure>
    <time_frame>change from baseline after 6 weeks treatment based on body composition by bioimpedance</time_frame>
    <description>Fat tissue: fat mass in Kilograms and percentage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolic profile</measure>
    <time_frame>Change from baseline after 6 weeks treatment based on glucose, total cholesterol, HDL-c, LDL-c, triglycerides, and HOMA-IR.</time_frame>
    <description>Changes in serum metabolic profile: mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of inflammation</measure>
    <time_frame>Change from baseline after 6 weeks treatment based on IL-1, IL-6 and PCR</time_frame>
    <description>Changes in serum markers of inflammation: pg/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical complications</measure>
    <time_frame>Surgical complications during hospitalization and up to 30 days after surgery 1) dehiscence of anastomosis, 2) intestinal obstruction, 3) intestinal stenosis</time_frame>
    <description>Prevalence of surgical complications (yes or no): 1) dehiscence of anastomosis, 2) intestinal obstruction, 3) intestinal stenosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events associated with phentermine</measure>
    <time_frame>Adverse events during and the end of 6-8 weeks of phentermine (blood pressure, cardiac frequency, headache, gastrointestinal symptoms, euphoria, anxiety and insomnia) associated with phentermine.</time_frame>
    <description>Determine the frequency and severity of adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Obesity</condition>
  <condition>Morbid Obesity</condition>
  <condition>Bariatric Surgery</condition>
  <condition>Non-alcoholic Fatty Liver</condition>
  <condition>Weight Loss</condition>
  <arm_group>
    <arm_group_label>Phentermine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low-calorie diet + Phentermine Capsules 15 mg po by 6 weeks, one time a day before bariatric surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Low-calorie diet + Placebo Capsules po by 6 weeks, one time a day before bariatric surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phentermine</intervention_name>
    <description>This is a randomized, control trial to investigate the effect and safety of Phentermine in patients with obesity who need a bariatric surgery (BMI &gt;35 kg/m2 with comorbidities or BMI &gt; 40 kg/m2).</description>
    <arm_group_label>Phentermine</arm_group_label>
    <other_name>Terfamex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>his is a randomized, control trial to investigate the effect and safety of Phentermine in patients with obesity who need a bariatric surgery (BMI &gt;35 kg/m2 with comorbidities or BMI &gt; 40 kg/m2).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women and men

          -  &gt;18 years and &lt;55 years old.

          -  Diagnosis of obesity grade II with comorbidities

          -  Diagnosis of obesity grade III with or without comorbidities

          -  Approved to bariatric surgery by an interdisciplinary committee

          -  Having signed the Informed consent form

        Exclusion Criteria:

          -  Use of addictive substances

               -  Inability or lack of understanding to achieve lifestyle and behaviour changes

               -  Mental disease

               -  Severe Pulmonary disease

               -  Giant Hiatal hernia, gastric or duodenal ulcer

               -  Unstable coronary artery disease

               -  Portal hypertension or esophageal varices

               -  Surgical or anesthetic high risk
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Pérez-Cruz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Juárez de México</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elizabeth Pérez-Cruz, MD</last_name>
    <phone>5557477569</phone>
    <phone_ext>7497</phone_ext>
    <email>pece_liz@yahoo.com.mx</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pérez-Cruz, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Juárez de México</name>
      <address>
        <city>Ciudad de México</city>
        <state>Cdmx</state>
        <zip>07760</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth PEREZ-CRUZ, MD</last_name>
      <phone>5557477560</phone>
      <phone_ext>7497</phone_ext>
      <email>pece_liz@yahoo.com.mx</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>January 2, 2019</study_first_submitted>
  <study_first_submitted_qc>February 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2019</study_first_posted>
  <last_update_submitted>February 20, 2019</last_update_submitted>
  <last_update_submitted_qc>February 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Juarez de Mexico</investigator_affiliation>
    <investigator_full_name>ELIZABETH PEREZ CRUZ</investigator_full_name>
    <investigator_title>Principal Investigator. MD. MSc</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Obesity treatment</keyword>
  <keyword>Non-alcoholic Fatty Liver</keyword>
  <keyword>Weight Loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phentermine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

